AUTHORS
Yuanyuan Ji, PhD, Toby Thomas2, Benjamin Kroger, BS3, Reiko Tachibana4, Jacob Lark, BS5, Bao Duy An Hoang, BS6, Amy Song, BS7, Jerry Yuen, BS8, Yazan F. Madanat, MD9, Peter Carlsgaard, MD10, Stephen Chung, MD11
AFFILIATIONS
1 University of Texas Southwestern, Dallas, Texas, United States
2 University of Texas Southwestern, Dallas, Texas, United States
3 University of Texas Southwestern, Dallas, Texas, United States
4 University of Texas Southwestern, Dallas, Texas, United States
5 University of Texas Southwestern, Dallas, Texas, United States
6 University of Texas Southwestern, Dallas, Texas, United States
7 University of Texas Southwestern, Dallas, Texas, United States
8 University of Texas Southwestern, Dallas, Texas, United States
9 University of Texas Southwestern, Dallas, Texas, United States, University of Texas Southwestern, Dallas, Texas, United States
10 University of Texas Southwestern, Dallas, Texas, United States
11 University of Texas Southwestern, Dallas, Texas, United States
ABSTRACT
AMLs enriched for HSC-like gene signatures have the worst clinical outcomes, yet the basis of this high-risk state is poorly understood. AML is sustained by leukemia stem cells (LSCs) that phenotypically resemble myeloid progenitors but acquire aberrant self-renewal by co-opting HSC programs to varying degrees. HSCs uniquely require low, tightly regulated protein synthesis; both increases and decreases impair self-renewal, while progenitors tolerate high synthesis rates. We previously showed CD99 promotes LSC self-renewal by restricting protein synthesis, suggesting some AMLs co-opt this HSC-like dependence. We hypothesized that HSC-like AMLs exhibit greater dependence on regulated protein synthesis.
In the MLL-AF9 (MA9) model, transducing HSCs or GMPs with MLL-AF9 generates AMLs sustained by aberrantly self-renewing GMPs (L-GMPs); HSC-derived AMLs are chemoresistant and display HSC-associated transcriptional programs linked to poor prognosis, mimicking high-risk AML. We generated HSC- and GMP-derived MA9 AMLs from wild-type (WT) and B6-Cd99Gt(pU-21T)44Imeg (CD99 KO) mice, measuring protein synthesis in vivo with OP-puromycin and LSC function by secondary transplant. L-GMPs from WT HSC MA9 AMLs had 50% lower protein synthesis than L-GMPs from WT GMP MA9 AMLs. CD99 loss increased protein synthesis in L-GMPs and impaired LSC function in HSC but not GMP MA9 AMLs. Using destabilized GFP (dGFP) as an in vivo protein synthesis reporter, we sorted dGFP-high and dGFP-low L-GMPs, finding that dGFP-low cells were enriched for LSC function in HSC but not GMP MA9 AMLs.
To test this dependence independently of CD99, we generated MA9 AMLs from mice with altered mTORC1 (Tsc1fl/fl;Mx1-Cre+, TSC1 KO and Raptorfl/fl;Mx1-Cre+, RAPTOR KO), mTORC2 (Rictorfl/fl;Mx1-Cre+, RICTOR KO), or ribosome biogenesis (Rpl24+/-). Both increased (Tsc1Δ/Δ) and decreased (RaptorΔ/Δ) mTORC1 signaling, as well as ribosomal insufficiency (Rpl24+/-), depleted LSCs in HSC but not GMP MA9 AMLs. RICTOR loss did not deplete LSCs, mirroring the known dispensability of mTORC2 in normal HSCs. The ribosome biogenesis inhibitor CX-5461 and the mTORC1 inhibitor rapamycin each selectively depleted LSCs in HSC MA9 AML.
The integrated stress response (ISR) suppresses global translation while selectively increasing ATF4 translation. Low-level ISR activation can promote adaptive cell survival, whereas high-level activation induces cell death. Using an ATF4 translation reporter, we found that HSC MA9 AMLs have elevated ISR activity. L-GMPs with high ATF4 reporter activity showed enhanced LSC function in HSC but not GMP MA9 AMLs, indicating HSC-like LSCs exist in a low-translation, high-ISR state.
Prior drug screens identified preferential venetoclax sensitivity in HSC-like AMLs, but its basis is unknown. Because venetoclax triggers mitochondrial release of cytochrome c, which can bind to and activate the ISR kinase HRI, we tested if ISR activation underlies its activity. In HSC MA9 AMLs, one venetoclax dose reduced disease burden, and 21 doses impaired LSC function as assessed by secondary transplant. The ISR inhibitor ISRIB completely rescued both effects, and Eif2ak1-/- (HRI KO) HSC MA9 AMLs were completely resistant to both regimens. In contrast, venetoclax had minimal effects on GMP MA9 AMLs. Thus, venetoclax exerts its activity against HSC-like AML by driving HRI-mediated ISR activation to suppress protein synthesis below a tolerable threshold. In venetoclax-treated AML patients (n=10), ATF4 reporter activity in pretreatment samples was 2.6-fold higher in responders than nonresponders (P=0.024).
Ribosome profiling revealed HSC MA9 AMLs exhibit translational repression of genes involved in Complex I biogenesis, ribosome biogenesis, and translation relative to GMP MA9 AMLs. Venetoclax further deepened this repression in HSC MA9 AMLs, with minimal translational effects in GMP MA9 AMLs. Accordingly, venetoclax synergized with the Complex I inhibitor IACS-010759 to deplete disease and prolong survival selectively in HSC MA9 AML.
These data establish that cell-of-origin determines whether an AML exhibits the normal HSC requirement for tightly regulated protein synthesis, revealing a therapeutically exploitable dependency in high-risk HSC-like AML. They also demonstrate that translational control is a principal mediator of venetoclax activity in these AMLs and nominate therapeutic combinations that further activate the ISR, disrupt regulated protein synthesis, or target Complex I.
DISCLOSURES
Yuanyuan Ji, PhD: No relevant conflicts of interest to declare.